Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Diverse Psychotomimetics Act Through a Common Signaling Pathway
Per Svenningsson,1Eleni T. Tzavara,2Robert Carruthers,1Ilan Rachleff,1Sigrid Wattler,3Michael Nehls,3David L. McKinzie,2Allen A. Fienberg,1,4George G. Nomikos,2Paul Greengard1*
Three distinct classes of drugs: dopaminergic agonists (suchas D-amphetamine), serotonergic agonists (such as LSD), andglutamatergic antagonists (such as PCP) all induce psychotomimeticstates in experimental animals that closely resemble schizophreniasymptoms in humans. Here we implicate a common signaling pathwayin mediating these effects. In this pathway, dopamine- and anadenosine 3',5'-monophosphate (cAMP)regulated phospho-proteinof 32 kilodaltons (DARPP-32) is phosphorylated or dephosphorylatedat three sites, in a pattern predicted to cause a synergisticinhibition of protein phosphatase1 and concomitant regulationof its downstream effector proteins glycogen synthesis kinase3(GSK-3), cAMP response elementbinding protein (CREB),and c-Fos. In mice with a genetic deletion of DARPP-32 or withpoint mutations in phosphorylation sites of DARPP-32, the effectsof D-amphetamine, LSD, and PCP on two behavioral parameterssensorimotorgating and repetitive movementswere strongly attenuated.
1 Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA. 2 Eli Lilly and Company, Lilly Corporate Center, Neuroscience Discovery Research, Indianapolis, IN 462850510, USA. 3 Lexicon Genetics Inc., The Woodlands, TX 773811160, USA. 4 Intra-Cellular Therapies Inc., Audubon Biomedical Science and Technology Park, New York, NY 10032, USA.
* To whom correspondence should be addressed. E-mail: greengd{at}mail.rockefeller.edu
ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities.
F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P. J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, et al. (2008)
J. Pharmacol. Exp. Ther.
327, 827-839
|Abstract »|Full Text »|PDF »
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection.
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. (2008)
Pharmacol. Rev.
60, 358-403
|Abstract »|Full Text »|PDF »
Dopamine Modulation of Prefrontal Cortex Interneurons Occurs Independently of DARPP-32.
H. Trantham-Davidson, S. Kroner, and J. K. Seamans (2008)
Cereb Cortex
18, 951-958
|Abstract »|Full Text »|PDF »
The B''/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A.
J.-H. Ahn, J. Y. Sung, T. McAvoy, A. Nishi, V. Janssens, J. Goris, P. Greengard, and A. C. Nairn (2007)
PNAS
104, 9876-9881
|Abstract »|Full Text »|PDF »
From prediction error to psychosis: ketamine as a pharmacological model of delusions.
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?.
C. H. Large (2007)
J Psychopharmacol
21, 283-301
|Abstract »|PDF »
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation.
P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard (2007)
J. Neurosci.
27, 4201-4209
|Abstract »|Full Text »|PDF »
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56{delta} subunit.
J.-H. Ahn, T. McAvoy, S. V. Rakhilin, A. Nishi, P. Greengard, and A. C. Nairn (2007)
PNAS
104, 2979-2984
|Abstract »|Full Text »|PDF »
DARPP-32 Involvement in the Photic Pathway of the Circadian System.
L. Yan, J. M. Bobula, P. Svenningsson, P. Greengard, and R. Silver (2006)
J. Neurosci.
26, 9434-9438
|Abstract »|Full Text »|PDF »
Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32..
Y. Zhang, P. Svenningsson, R. Picetti, S. D. Schlussman, A. C. Nairn, A. Ho, P. Greengard, and M. J. Kreek (2006)
J. Neurosci.
26, 2645-2651
|Abstract »|Full Text »|PDF »
Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons.
M. Andersson, A. Usiello, A. Borgkvist, L. Pozzi, C. Dominguez, A. A. Fienberg, P. Svenningsson, B. B. Fredholm, E. Borrelli, P. Greengard, et al. (2005)
J. Neurosci.
25, 8432-8438
|Abstract »|Full Text »|PDF »
Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function.
J. H. Krystal, E. B. Perry Jr, R. Gueorguieva, A. Belger, S. H. Madonick, A. Abi-Dargham, T. B. Cooper, L. MacDougall, W. Abi-Saab, and D. C. D'Souza (2005)
Arch Gen Psychiatry
62, 985-994
|Abstract »|Full Text »|PDF »
cAMP and Extracellular Signal-Regulated Kinase Signaling in Response to D-Amphetamine and Methylphenidate in the Prefrontal Cortex in Vivo: Role of {beta}1-Adrenoceptors.
V. Pascoli, E. Valjent, A.-G. Corbille, J.-C. Corvol, J.-P. Tassin, J.-A. Girault, and D. Herve (2005)
Mol. Pharmacol.
68, 421-429
|Abstract »|Full Text »|PDF »
Predictors of schizophrenia--a review.
P. Maki, J. Veijola, P. B. Jones, G. K. Murray, H. Koponen, P. Tienari, J. Miettunen, P. Tanskanen, K.-E. Wahlberg, J. Koskinen, et al. (2005)
Br. Med. Bull.
73-74, 1-15
|Abstract »|Full Text »|PDF »
From The Cover: Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum.
E. Valjent, V. Pascoli, P. Svenningsson, S. Paul, H. Enslen, J.-C. Corvol, A. Stipanovich, J. Caboche, P. J. Lombroso, A. C. Nairn, et al. (2005)
PNAS
102, 491-496
|Abstract »|Full Text »|PDF »
Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3',5'-Monophosphate-Regulated Phosphoprotein of 32 kDa "Knockout" Mutants Congenic on the C57BL/6 Genetic Background.
R. E. Nally, A. Kinsella, O. Tighe, D. T. Croke, A. A. Fienberg, P. Greengard, and J. L. Waddington (2004)
J. Pharmacol. Exp. Ther.
310, 1281-1287
|Abstract »|Full Text »|PDF »
Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway".
Response to Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway".
P. Svenningsson, G. G. Nomikos, and P. Greengard (2004)
Science
305, 180d
|Full Text »|PDF »
Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins.
P. B. Allen, A. T. Greenfield, P. Svenningsson, D. C. Haspeslagh, and P. Greengard (2004)
PNAS
101, 7187-7192
|Abstract »|Full Text »|PDF »
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.
J.-M. Beaulieu, T. D. Sotnikova, W.-D. Yao, L. Kockeritz, J. R. Woodgett, R. R. Gainetdinov, and M. G. Caron (2004)
PNAS
101, 5099-5104
|Abstract »|Full Text »|PDF »
Psychotomimetic Effects of Drugs -- A Common Pathway to Schizophrenia?.
D. J. Gerber and S. Tonegawa (2004)
N. Engl. J. Med.
350, 1047-1048
|Full Text »|PDF »
Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum.